Beam Therapeutics Inc. buy thesis: base-editing gene therapy leaders, risto-cel & BEAM-302 catalysts, strong cash runway.

Beam Therapeutics BEAM shares are rising Tuesday after the company reported quarterly results. Beam Therapeutics stock is surging to new heights today. What’s fueling BEAM momentum? Beam Surpasses ...

Beam Therapeutics is a biotech firm focused on developing precision genetic treatments using base editing technology. The company has secured $675 million in upfront payments from agreements with ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Beam Therapeutics Inc. (BEAM) is a stock that can certainly grab ...

Beam Global (BEEM) shares surged nearly 11% in Wednesday’s pre-market trade after the company announced that it has received ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...

Shares of Beam Therapeutics BEAM were up 22.3% on Monday after the company outlined strategic priorities and some expected milestones related to its gene therapy pipeline candidates for 2026. Beam ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands ...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) was upgraded by equities research analysts at Bank of America from a “neutral” rating to a “buy” rating in a report released on Friday, Marketbeat.com ...